Co-Authors
This is a "connection" page, showing publications co-authored by MEDIGET TESHOME and RACHEL M. LAYMAN.
Connection Strength
0.807
-
Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Ann Surg Oncol. 2024 Oct; 31(11):7326-7334.
Score: 0.242
-
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Breast Cancer Res Treat. 2024 Apr; 204(2):289-297.
Score: 0.232
-
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250.
Score: 0.225
-
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
Score: 0.055
-
Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol. 2022 Oct; 29(10):6381-6392.
Score: 0.052